Private Equity Veterinary: Top Firms in 2026

Key Facts

• More than 35 companies are actively acquiring veterinary practices in the US, with over 20 PE-backed platforms operating nationally as of 2026.
• Private equity firms deployed $51.6 billion into the veterinary sector from 2017 to 2023, with an additional $9.3 billion in the first four months of 2024 alone.
• Corporate entities now own approximately 25-30% of general practices, up from 8% a decade ago. Corporations already own about 75% of specialty and emergency clinics.
• The largest single PE-backed consolidator by practice count is National Veterinary Associates, backed by JAB Consumer Partners, with over 1,013 practices.
• VetCor, backed by Harvest Partners alongside Cressey & Co., ranked as the most active acquirer in 2023-2024, growing to 917 practices.
• Veterinary services prices rose 9.6% year-over-year as of March 2024, nearly triple the 3.5% overall consumer price inflation rate over the same period.
• An estimated 70-85% of general practices remain independent, signaling a long consolidation runway ahead for PE-backed platforms.

Veterinary Private Equity: Market Overview

The US veterinary industry spans approximately 30,000 clinics and generates $38 billion in companion animal health care spending annually, up from $29 billion in 2019. That growth attracted leading veterinary private equity firms beginning in the early 2000s, drawn by a fragmented ownership structure dominated by independent practices. Consolidation accelerated sharply during 2020 to 2022, when a pandemic-driven surge in pet ownership created peak investment conditions.

The investment thesis rests on two structural advantages. Veterinary practices operate on a cash-pay model, insulating them from reimbursement risk. Practices with $2-10 million in EBITDA (earnings before interest, taxes, depreciation, and amortization) are typical lower middle market targets. Those with $20-75 million EBITDA attract larger buyout funds. General partners raise capital from limited partners including pension funds, endowments, sovereign wealth funds, and insurance companies. They then deploy that capital through platform acquisitions followed by systematic bolt-on purchases of independent practices.

California and Texas are focal points for regulatory scrutiny. The Federal Trade Commission required JAB Consumer Partners to divest clinics in both states in 2022. Iowa, Minnesota, New Jersey, New York, and North Carolina have laws restricting non-veterinarian ownership of practices. Despite that regulatory backdrop, PE and venture capital investment in pet care surged 659% in 2023 to $2.89 billion in deal value, reflecting sustained conviction in the consolidation thesis.

PE-Backed Platforms: Firm Comparison

The consolidator market ranges from global family office operators with 2,000-plus facilities to newly formed PE-backed platforms with under 100 practices. The table below covers the major platforms currently operating in the US, sorted by total practice count.

Most veterinary-focused PE funds do not publicly disclose AUM figures. KKR manages approximately $500 billion in diversified assets, making it the largest fund manager by AUM with a named veterinary portfolio company.

The general practice roll-up segment accounts for the bulk of deal volume. Specialty and emergency commands premium EBITDA multiples. With approximately 75% of that segment already under corporate ownership, supply constraints sustain elevated valuations for remaining independent targets.

Best Firms by Strategy

Most Active General Practice Acquirer (2023-2024): VetCor (Harvest Partners) grew to 917 practices, ranking as the single most aggressive bolt-on acquirer in the last 24 months.

Mega-Buyout Leader: JAB Consumer Partners (NVA at 1,013 practices plus Ethos at 154) holds the most concentrated PE-backed position in veterinary. A 2022 FTC consent decree restricts the firm's future specialty acquisitions in California and Texas.

Largest Family Office Platform: Mars (Banfield, VCA, BluePearl combined 2,000-plus practices) operates as a permanent hold with no exit pressure, structurally different from any PE fund.

Strongest Mid-Market Growth Equity Track Record: Shore Capital Partners backed Southern Veterinary Partners and Mission Veterinary Partners separately, then orchestrated their planned merger into a 730-plus-practice combined entity.

Top Specialty and Emergency Investor: SkyKnight Capital and Goldman Sachs Merchant Banking (MedVet Associates, 38 specialty practices) operate in the highest-multiple segment with focused sector expertise.

Growth Equity Urban Model: Warburg Pincus (Bond Vet, 50 practices) is the only major backer focused exclusively on urban primary care, differentiating from the suburban general practice roll-up model.

New Platform Momentum: Chicago Pacific Founders (Pieper Veterinary) and Varsity Healthcare Partners (VetEvolve) both launched in 2024, confirming that uncommitted capital continues entering the space.

Institutional-Grade Exposure for LPs: KKR's PetVet Care Centers (456 practices since 2017) provides the most established PE fund track record in general practice consolidation.

Top PE-Backed Consolidators in Detail

VetCor (Harvest Partners + Cressey & Co.)

The most active acquirer in the veterinary roll-up space from 2023 to 2024, VetCor has reached 917 practices under New York-based Harvest Partners, alongside co-investor Cressey & Co. Its pace of bolt-on acquisitions has outstripped every competing consolidator over that window, making it the clearest illustration of the buy-and-build strategy at scale. Founders approaching retirement with a general practice generating $2-10 million in EBITDA have strong reason to prioritize VetCor. Its demonstrated acquisition momentum and committed capital make it the platform with the highest current deal velocity.

National Veterinary Associates (JAB Consumer Partners)

JAB Consumer Partners combines NVA's 1,013 practices with Ethos Veterinary Health's 154 specialty hospitals, giving it the broadest sector coverage of any single investment firm operating in veterinary care. JAB acquired NVA in 2019 in a secondary buyout from Ares Management and OMERS, one of the defining recapitalization events in veterinary PE history. NVA is planning an initial public offering in 2025 or 2026, which would represent the first major veterinary consolidator IPO and a significant liquidity event for JAB's limited partners.

KKR (PetVet Care Centers)

KKR's veterinary investment thesis centers on applying its $500-billion-plus institutional infrastructure to a fragmented general practice market. The firm first invested in PetVet Care Centers in 2017 and has grown the platform to 456 practices through sustained bolt-on acquisition activity. Institutional LPs building diversified alternatives portfolios will find PetVet the most credentialed fund manager exposure to general practice consolidation currently available.

Shore Capital Partners (Southern + Mission Veterinary Partners)

Shore Capital's twin-platform model sets it apart from every other fund manager in this sector. The Chicago-based growth equity firm separately backed Southern Veterinary Partners (380 practices, headquartered in Birmingham, Alabama) and Mission Veterinary Partners (275 practices). It then initiated a planned merger creating a 730-plus-practice combined entity. That sequential build-and-merge approach demonstrates how a lower middle market firm can engineer scale comparable to mega-fund platforms without a comparable fund size.

TSG Consumer Partners (Thrive Pet Healthcare)

TSG Consumer Partners built Thrive Pet Healthcare into a 369-practice network using a consumer brand philosophy: deliberately not rebranding acquired practices preserves local clinic names and maintains client relationships. The San Francisco-based firm's Thrive subsidiary closed the only 24-hour emergency veterinary clinic in the Rochester, New York metro area. That decision prompted a formal FTC inquiry by local legislators and drew national attention to the service-access risks that can accompany PE-driven rationalization decisions.

AmeriVet (AEA Investors LP + AIDA)

AmeriVet's defining characteristic is its explicit positioning as a partnership model rather than a traditional roll-up. Backed by AEA Investors LP and AIDA since 2017, the platform has grown to 215 practices nationally while publicly arguing that its structure preserves veterinarian clinical autonomy and practice culture post-acquisition. Sellers who rank cultural continuity alongside purchase price will find AmeriVet's stated philosophy the most directly articulated among the active general practice consolidators.

Warburg Pincus (Bond Vet)

Warburg Pincus placed a category-creation bet when it backed Bond Vet's urban primary care concept, now at 50 practices concentrated in high-density city markets. Bond Vet's appointment-based format and urban clinic design stand apart from the suburban general practice acquisition model dominating the consolidator landscape. The platform represents growth equity applied to a differentiated thesis, making it structurally distinct from every other named platform in this market.

MedVet Associates (SkyKnight Capital + Goldman Sachs Merchant Banking)

The highest acquisition multiples in veterinary care belong to specialty and emergency, and MedVet is the leading independent specialty-focused platform with 38 practices, backed by SkyKnight Capital and Goldman Sachs Merchant Banking in Columbus, Ohio. Corporations already own approximately 75% of specialty practices, creating a supply-constrained market where buyer concentration gives selling owners significant negotiating leverage. Independent specialty hospitals evaluating a sale will encounter more competitive bidding and higher per-practice valuations than in any other segment.

Investment Trends Shaping the Market

The Moderation of Multiples Under Rate Pressure

Peak acquisition years of 2020 to 2022 coincided with near-zero interest rates, allowing PE funds to finance roll-ups with cheap variable-rate debt. Rising rates since 2022 have compressed EBITDA multiples toward the lower end of the 2x-to-10x acquisition range documented for the sector. Platforms that accumulated high leverage ratios during that window face ongoing debt service pressure. Analysts have flagged this as a potential trigger for distressed sales or clinic closures if rates remain elevated through 2026.

Specialty Clinics as Supply-Constrained Premium Assets

Roughly 75% of specialty and emergency practices are already under corporate ownership, creating a scarcity premium for remaining independent targets. JAB's Ethos Veterinary Health (154 practices), Mars's BluePearl (97 practices), and MedVet (38 practices) dominate the specialty tier. The FTC's 2022 consent decree restricted JAB's ability to add specialty acquisitions within 25 miles of existing holdings in California and Texas, making markets outside those zones significantly more competitive for specialty acquirers.

Expansion Beyond Clinics into the Pet Economy

Fund managers are extending their investment thesis well past veterinary practice acquisition. Blackstone acquired Rover.com for $2.3 billion in November 2023, paying a premium for the nation's largest pet sitting and dog walking platform. JAB Consumer Partners acquired multiple major US and European pet insurance companies between 2022 and 2024, positioning itself across the full pet care value chain from clinic visit through insurance claim.

New Platform Formation Signals Continued Dry Powder

Two new platforms launched in 2024: Pieper Veterinary (Chicago Pacific Founders) and VetEvolve (Varsity Healthcare Partners). Six platform transactions closed in the twelve months to mid-2024, confirming that general partners see sufficient independent practice supply to justify continued platform formation. With 70-85% of general practices remaining independent, the addressable acquisition market remains large despite a decade of consolidation.

Regulatory and Antitrust Pressure Reshaping Deal Structures

The FTC's action against JAB established that serial acquisition strategies are within regulatory reach even when individual deal sizes fall below standard review thresholds. The UK Competition and Markets Authority launched an investigation in 2024 into veterinary market concentration, drawing what regulators described as an unprecedented public response. US advocacy groups are pushing for Hart-Scott-Rodino Act revisions that would require pre-merger notification for smaller veterinary acquisitions. Those changes would add material compliance costs and timelines to current roll-up strategies.

How to Evaluate Veterinary Private Equity Firms

Acquisition track record is the most concrete signal of platform credibility. The average PE veterinary investment lasts 3.75 years before exit or secondary sale. Practice owners should ask directly about a fund's current lifecycle stage and how much uncommitted capital remains for bolt-on acquisitions. A platform in late fund cycle with limited dry powder is a weaker acquirer than one with a freshly raised fund and an active pipeline.

Deal terms vary significantly across buyers. Management fees typically run 1.5-2% of revenue, and the general partner's performance fee (carried interest) sits at roughly 20% of profits. Sellers negotiating a transaction should retain an experienced M&A advisor and assess the earn-out structure carefully before signing a letter of intent. Evaluating equity rollover provisions is also critical to participating in the eventual exit upside.

Cultural alignment shows up most reliably in staff retention and rebranding decisions post-acquisition. Research shows 84% of independent practice owners report high job satisfaction, versus significantly higher burnout rates in corporate settings. Requesting references from practice owners who sold to the platform 12-24 months prior provides direct evidence of how the consolidator operates after the acquisition closes.

FTC consent decree history is a meaningful due diligence checkpoint that takes under 30 minutes to verify. Platforms under active antitrust oversight face geographic restrictions that can limit their ability to acquire practices in specific markets. Sellers in California or Texas should confirm whether a prospective buyer faces FTC acquisition restrictions before entering negotiations. These restrictions can materially affect available deal options.

Which Firm Fits Your Needs?

Practice owners approaching retirement with a $5-15 million EBITDA general practice should engage VetCor, Shore Capital's platforms, AmeriVet, and Alliance Animal Health as primary targets. These platforms actively deploy capital into general practice bolt-on acquisitions, with documented integration processes and established practice count growth in the 200-900 range. AmeriVet's explicit partnership framing makes it the most logical starting point for owners who rank culture preservation above maximum purchase price.

Owners of specialty or emergency hospitals will attract a different buyer pool with more competitive dynamics. MedVet, Ethos Veterinary Health, and BluePearl are the established specialty consolidators. Independent specialty hospitals outside JAB's FTC-restricted zones can expect the highest EBITDA multiples in the sector. Retaining an investment banker with veterinary M&A experience is essential in specialty transactions. Buyer concentration is high, and information asymmetry strongly favors well-resourced acquirers.

LPs evaluating veterinary consolidation as an asset class should weigh KKR's PetVet Care Centers as the most institutionally credentialed option. The firm's $500-billion-plus asset management infrastructure and a PetVet track record stretching back to 2017 set it apart from newer entrants. LPs with a longer time horizon may find OMERS's pension fund structure, or the permanent capital model represented by Mars, better aligned with their mandate than a traditional 10-year PE fund cycle. NVA's anticipated IPO in 2025-2026 will provide the first major public market valuation benchmark for the consolidator sector.

Methodology

This guide covers veterinary private equity firms active in the US market as of early 2026, compiled from publicly documented deal activity, regulatory filings, and industry data covering practice counts, investment history, and regulatory actions. Firm profiles rely on verified practice counts and confirmed PE backer relationships. The guide excludes AUM and fund size figures where data is not publicly disclosed. Practice count, strategic significance, and recency of investment activity determined which 14 platforms are profiled here. Where data providers were cited in source material, the guide used the underlying figures without attributing specific brand names, consistent with standard editorial practice.